Larsucosterol for Alcoholic Hepatitis

This trial tests a new treatment called larsucosterol for individuals with severe alcohol-related liver disease, specifically severe alcoholic hepatitis. The researchers aim to determine if larsucosterol can help patients survive without needing a liver transplant over a 90-day period. Participants will receive either the actual treatment or a placebo (a substance with no therapeutic effect) to compare results. Suitable candidates have recently experienced jaundice (yellowing of the skin), consume large amounts of alcohol regularly, and are willing to join an alcohol abstinence support program. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially life-saving treatment advancements.

The trial information does not specify if you need to stop taking your current medications. However, it does exclude participants using systemic corticosteroids for current alcoholic hepatitis before enrollment. It's best to discuss your specific medications with the trial team.

Research has shown that larsucosterol is generally safe for people. Earlier studies found it well-tolerated at doses of 30 mg, 90 mg, and 150 mg in patients with alcohol-related liver disease. Most participants did not experience serious side effects. These findings suggest that larsucosterol does not cause major problems for those who take it. However, as with any treatment, monitoring for side effects remains important.¹²³⁴⁵

Larsucosterol is unique because it offers a fresh approach to treating alcoholic hepatitis, a condition where treatment options are currently limited mainly to steroids and supportive care. This drug stands out due to its novel mechanism of action, targeting the underlying liver inflammation in a new way that could potentially offer better outcomes. Researchers are particularly excited about Larsucosterol because it's administered as an intravenous infusion, which might provide faster relief from symptoms compared to traditional treatments. This could be a game-changer for patients who need rapid intervention.

Research has shown that larsucosterol may significantly reduce the risk of death in people with severe alcohol-related liver disease, known as alcohol-associated hepatitis (AH). Earlier studies found that patients treated with larsucosterol had better survival rates. Specifically, one study showed that the death rate dropped by more than 50% for those receiving this treatment. Larsucosterol works by influencing gene expression, which may help improve liver health. Although no approved treatment for AH currently exists, these early findings suggest that larsucosterol could be a helpful option. Participants in this trial will receive either larsucosterol or a placebo to further evaluate its effectiveness.¹³⁵⁶⁷